Mumbai: The Medicines and Medical Devices Agency from the Republic of Moldova has invited Indian pharma companies to register and export 141 pharmaceutical products for the treatment of chronic ailments like TB, HIV, hypertension, cardiac disorders and mental disorders, among others.
The Medicines and Medical Devices Agency is responsible for the registration of medical products in Moldova.
Medicines include phenylephrinum for cough related allergies, dobutamine for the treatment of cardiogenic shock and severe heart failure, argininum+sorbitolum to treat hypertension, tenofoviri disoproxili fumaras+lamivudinum+ dolutegravirum for the treatment of HIV, amoxicillinum+acidum clavulanic for the treatment of bacterial infections, tenofovir alafenamide for the treatment of hepatitis B infection, morphinum which is used as an analgesic, rifapentinum+isoniazidum to treat latent TB infection, linezolidum, which is an antibiotic used for the treatment of infections caused by gram-positive bacteria that are resistant to other antibiotics, antipsychotic medication haloperidolum, methylphenidate for treating attention deficit hyperactivity disorder (ADHD) in children and lamivudinum used to prevent and treat HIV/AIDS among others.
“We would like to bring to the notice of member companies that The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is in receipt of communication from the Department of Pharmaceuticals (DoP) that the Republic of Moldova has shared a list of 141 pharmaceutical products required by Moldova. Member companies are requested to go through the list and share their willingness to supply the medicines preferably by November 10, 2023, to enable Council to share the list with the DoP and the Embassy of the Republic of Moldova to the Republic of India,” informed Uday Bhaskar, director general (DG), Pharmexcil.
“The proposal of Moldova is to initially identify Indian pharmaceutical exporters who are keen to explore this opportunity. Following that, the Medicines and Medical Devices Agency will get involved regarding regulatory and quality certification requirements,” Bhaskar further added.
The Republic of Moldova is a lower-middle-income country in Eastern Europe. The country was part of the former Soviet Union, from which it obtained independence in 1991. Since independence, Moldova, including its health sector, has undergone profound social, political and economic transformations. While some reforms were introduced in the hospital sector, much remains to be done and the most important changes so far were compelled by the introduction of a mandatory health insurance system in 2004. These included strengthening of primary health care and ensuring access to a limited number of medicines in privatised pharmacies and selected national programmes e.g. insulin, rare diseases, tuberculosis (TB), HIV/AIDS, immunisation.
Pharmaceutical sales in Moldova will grow over our extended forecast period, driven by increasing demand and improving access to medicines. While the generics segment will remain the dominant option, patented medicines will edge higher in terms of market share by 2032.